Research

Evidence supporting the use of medical cannabis

Research Studies Worldwide

For over 40 years, scientists and clinicians have studied the therapeutic efficacy of cannabis, its extracts, and refined phytochemicals. This research is accompanied by a significant amount of anecdotal evidence and case reports of therapeutic benefit.

There are 400+ clinical studies in progress around the globe

*Source: US National Library of Medicine. Last updated June 2018.

Chronic pain in adults

“There is substantial evidence that cannabis is an effective treatment for chronic pain in adults.”

 

 

Chemotherapy-induced nausea and vomiting

“There is conclusive evidence that oral cannabinoids are effective antiemetics in the treatment of chemotherapy‑induced nausea and vomiting.”

Muscle spasticity in multiple sclerosis (MS)

“There is substantial evidence that oral cannabinoids are an effective treatment for improving patient-reported multiple sclerosis spasticity symptoms.” *

* Source: National Academies of Sciences, Engineering, and Medicine (2017) In, “The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research”

 

Canopy Health Innovations

CHI is a biopharmaceutical company that develops innovative cannabis-based products to create a range of effective formulations and delivery mechanisms and research their therapeutic effects.

 

Spectrum Cannabis, as a sister company, aims to leverage this R&D to improve the quality of life and health of those suffering from acute and chronic illnesses worldwide.

CHI has recently filed eight provisional US patents relating to studies in:
 
  • Fibromyalgia

  • Amyotrophic Lateral Sclerosis (also known as ALS, Lou Gehrig's disease)

  • Anxiety and its various sub-groups (in humans and animals, in conjunction with Canopy Animal Health)

  • Cognitive enhancement (in humans and animals, in conjunction with Canopy Animal Health)

  • Pain and various sub-groups (in humans and animals, in conjunction with Canopy Animal Health)

  • Opioid sparing, pain management, and addiction (through Beckley Canopy Therapeutics)

Investigator-initiated research

Through our research programs, CHI’s aim is to create natural plant-based medicines and health products derived from cannabis to improve the quality of life for those affected by acute and chronic illness. Our primary research area is within neuroscience.

 

We support applicants who are rigorous with their research and committed to advancing cannabinoid science.

 

This website uses cookies to recognize your computer or device to give you the best user experience and to improve its features. You can disable cookies through your browser but some features of the site will no longer be available. To read our Website Privacy Statement, click here.